Stifel analyst Eric Le Berrigaud downgraded Novartis to Hold from Buy with a price target of CHF 106, up from CHF 103. The analyst sees “more limited upside” potential for the shares, saying most of the expected key catalysts for the year have already passed. The firm believes 2025 will be “much more difficult” for Novartis compared to 2024.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis receives FDA priority review for CML in adults
- Novartis price target raised to CHF 86 from CHF 77 at Berenberg
- Novartis downgraded to Hold from Buy at Deutsche Bank
- NVS Earnings: Novartis Beats Q2 Estimates, Raises Profitability Outlook
- Options Volatility and Implied Earnings Moves Today, July 18, 2024